Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
This study has been terminated.
( Terminated due to safety concerns )
Study NCT00687596   Information provided by Taiho Oncology, Inc.

First Received on May 28, 2008.   Last Updated on June 4, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Sponsors listed in this trial